REFERENCES
- Ishizaka K, Ishizaka T, Terry W D. Antigenic structure of gamma-E globulin and reaginic antibody. J Immunol 1967; 99: 849–858, [PUBMED], [INFOTRIEVE], [CSA]
- Presta L G, Lahr S J, Shields R L, Porter J P, Gorman C M, Fendly B M, Jardieu P M. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623–2632, [PUBMED], [INFOTRIEVE], [CSA]
- Shields R L, Werther W R, Zioncheck K, O'Connell L, Fendly B, Presta L G, Thomas D, Saban R, Jardieu P. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107: 308–312, [PUBMED], [INFOTRIEVE], [CSA]
- Liu J, Lester P, Builder S, Shire S J. Characterization of complex formation by humanized anti-E monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34: 10474–10482, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Easthope S, Jarvis B. Omalizumab. Drugs 2001; 61: 253–260, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- MacGlashan D, Lichtenstein L M, Mc Kenzie-White J, Chichester K, Henry A J, Sutton B J, Gould H J. Upregulation of FcεRI on human basophils by IgE antibody is mediated by interaction of IgE with FcεRI. J Allergy Clin Immunol 1999; 104: 492–498, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tsicopoulos A, Joseph M. The role of CD23 in allergic disease. Clin Exp Allergy 2000; 30: 602, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- MacGlashan D W, Jr, Bochner B S, Adelman D C, Jardieu P M, Togias A, McKenzie-White J, Sterbinsky S A, Hamilton R G, Lichtenstein L M. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438–1445, [PUBMED], [INFOTRIEVE], [CSA]
- Lin H, Boesel K M, Griffith D T, Prussin C, Foster B, Romero F A, Townley R, Casale T B. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J. Allergy Clin Immunol 2004; 113: 297–302, [CROSSREF], [CSA]
- Prussin C, Griffith D T, Boesel K M, Lin H, Foster B, Casale T B. Omalizumab treatment downregulates dendritic cell FeεRI expression. J Allergy Clin Immunol 2003; 112: 1147–1154, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Beck L A, Marcotte G V, Mac Glashan D, Togias A, Saini S. Omalizumabinduced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004; 114: 527–530, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Maurer D, Fiebiger E, Reininger B, Ebner C, Petzelbauer P, Shi G P, Chapman H A, Stingl G. Fc ε receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J Immunol 1998; 161: 2731–2739, [PUBMED], [INFOTRIEVE], [CSA]
- Rissoan M C, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu Y J. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183–1186, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Foster B, Metcalfe D D, Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol 2003; 112: 1132–1138, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bates C A, Silkoff P E. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003; 111: 256–262, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Silkoff P E, Romero F A, Gupta N, Townley R G, Milgrom H. Exhaled nitric oxide in children with asthma receiving xofair (omializuma), a monoclonal anti-immunoglobulin E antibody. Pediatrics 2004; 113: 308–312, [CROSSREF], [CSA]
- Djukanović R, Wilson S J, Kraft M, Jarjour N N, Steel M, Chung K F, Bau W, Fowler-Taylor A, Matthews J, Busse W W, Holgate S T, Fany J V. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. AM J Respir Crit Care Med 2004; 170: 583–593, [CROSSREF], [CSA]
- Fahy J V, Flemin H E, Wong H H, Liu J T, Su J O, Reimann J, Fick R B, Jr, Boushey H A. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. AM J Respir Crit Care Med 1997; 155: 1828–1834, [PUBMED], [INFOTRIEVE], [CSA]
- Boulet L P, Chapman K R, Cote J, Kalra S, Bhagat R, Swaystun V A, Laviolette M, Cleland L D, Deschesnes F, Su J O, DeVault A, Fick R B, Jr, Cockcroft D W. Inhibitory effects of an anti-IgE antibody E25 on aftergen-induced early asthmatic response. AM J Respir Crit Care Med 1997; 155: 1835–1840, [PUBMED], [INFOTRIEVE], [CSA]
- Milgrom H, Fick R B, Su J O, Reimann J D, Bush R K, Watrous M L, Metzger W J. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341: 1966–1973, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Busse W, Corren J, Lanier B O, Mc Alary M, Fowler-Taylor A, Cioppa G D, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–190, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, Mc Alary M, Taylor A F, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108: E36, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Solér M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–261, [CROSSREF], [CSA]
- Corren J, Casale T B, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111: 87–90, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, and anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378–1386, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Holgate S T, Chuchalin A G, Hebert J, Lotvall J, Persson G B, Chung K F, Bousquet J, Kerstjens H A, Fox H, Thirlwell J, Cioppa G D. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632–638, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Oba Y, Salzman G A. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114: 265–269, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ayres J G, Higgins B, Chilvers E R, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701–708, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa G D. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302–308, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh K M, Ramos S, Canonica G W, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–316, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dykewicz M S, Fineman S. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518, [PUBMED], [INFOTRIEVE], [CSA]
- Blaiss M S. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 449–454, [PUBMED], [INFOTRIEVE], [CSA]
- Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma (ARIA) in collaboration with the world health organization. J Allergy Clin Immunol 2001; 108: S147–S336, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dykewicz M S. Rhinitis and sinusitis. Implications for severe asthma. Immunol Allergy Clin N Am 2001; 21: 427, [CROSSREF], [CSA]
- Greenberger P A. Interactions between rhinitis and asthma. Allergy Asthma Proc 2004; 25: 89–93, [PUBMED], [INFOTRIEVE], [CSA]
- Corren J, Manning B E, Thompson S F, Hennessy S, Strom B L. Rhinitis therapy and the prevention of hospital care for asthma: A case-control study. J Allergy Clin Immunol 2004; 113: 415–419, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa G D, Sandstrom T. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253–259, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Casale T B, Condemi J, La Force C, Nayak A, Rowe M, Watrous M, Mc Alary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G. Effect of omalizumab on symptoms of seasonal allergic rhinitis. JAMA 2001; 286: 2956–2967, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, Shen H, Fox H. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 160–167, [PUBMED], [INFOTRIEVE], [CSA]
- Hanf G, Noga O, O'Connor A, Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 2004; 23: 414–418, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vignola A M, Humbert M, Bousquet J, Boulet L P, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59: 709–717, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Package insert. Xolair (omalizumab). Aventis, East Hanover, NJ June, 2003
- Prescribing information: Summary of product characteristics, Available at: http://www.xolair.com
- Schoenwetter W, Gupta N, Liu J. Omalizumab, an anti-immunoglobulin E antibody, is not associated with an increased risk of immunological reactions [abst]. Eur Respir J 2002; 20(suppl 38), abst P741[CSA]
- Berger W, Gupta N, Mc Alary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 182–188, [PUBMED], [INFOTRIEVE], [CSA]
- Durham S R, Till S J. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 157–164, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gehlar K, Schlaak M, Becker W-M, Buffe A. Monitoring allergen Immunotherapy of pollen-allergic patients: The ration of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Expe Allergy 1999; 29: 497–506, [CROSSREF], [CSA]
- Guerra F, Carracedo J, Solana-Lara R, Sanchez-Guijo P, Ramirez R. Th2 lymphocytes from atopic patients treated with immunotherapy undergo rapid apoptosis after culture with specific allergens. J Allergy Clin Immunol 2001; 107: 647–653, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yssel H, Lecart S, Pene J. Regulatory T cells and allergic asthma. Microbes an Infect 2001; 3: 899–904, [CROSSREF], [CSA]
- Muller U, Akdis C A, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101: 747–754, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Akdis C A, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific Immunotherapy. J Clin Ivest 1998; 102: 98–106, [CSA]
- Casale T B. Experience with monoclonal antibodies in allergic mediated disease: Seasonal allergic rhinitis. J Allergy Clin Immunol 2001; 108(2)S84–S88, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997; 9: 805–814, [PUBMED], [INFOTRIEVE], [CSA]
- Shields R L, Werther W R, Zioncheck K, O'Connell L, Klassen T, Fendly B, Presta L G, Jardieu P M. Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. Int Arch Allergy Immunol 1995; 107: 412–413, [PUBMED], [INFOTRIEVE], [CSA]
- Schoenhoff M, Lin Y, Froehlich J, Fick R, Bates D. A pharmacodynamic model describing free IgE concentrations following administration of a recombinant humanized monoclonal IgE antibody in humans [abst]. Pharm Res 1995; 12: 411, [CSA]
- Fox J A, Hotaling T E, Struble C, Ruppel J, Bates D J, Schoenfohh M B. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279: 1000–1008, [PUBMED], [INFOTRIEVE], [CSA]
- Casale T B, Busse W W, Kline J N, Ballas Z K, Moss M H, Townley R G, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117(1)134–140, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]